Recently, our President and Managing Director, Jennifer Che, participated as a speaker at the HKSTP Market Discovery - BIO Connect event, hosted by HKSTP and InvestHK. This exclusive gathering brought together international biotech disruptors, offering them valuable insights into accessing the vast markets of Asia and beyond.

In her talk titled "Biotech Disruptors Benefit from HK IP," Jennifer highlighted the unique advantages Hong Kong offers from an intellectual property perspective. She discussed the rapidly developing IP ecosystem, including the homegrown original grant patent system and various tax and funding incentives that make the region an attractive hub for research and development. Additionally, she emphasized the expertise of local firms like Eagle IP, which are adept at navigating the complex IP challenges within the Greater Bay Area.

Our Past Events

Recommended Insights

FOLLOW UP: Amendments to the China Patent Examination Guidelines in 2022 – Part 1: New rules for designs in view of China signing onto the Hague Agreement

4 January 2023

Since the publication of our earlier article about China signing onto the Hague Agreement, some of our Hong Kong clients have expressed interest in taking advantage of the Hague international design application system, i.e., filing a Hague international design application with the CNIPA (Chinese National Intellectual Property Administration) as a receiving office (RO). Up until […]

China’s Newest Examination Guidelines: Inventive Step for Biological / Life Science Inventions (Part III)

30 April 2021

This is Part III of a three-part series summarizing the Examination Guidelines that were released by the CNIPA on January 15, 2021, one year to the date of Phase 1 of the US and China Economic and Trade Agreement. That agreement included specific provisions where China "shall permit pharmaceutical patent applicants to rely on supplemental […]

IP Strategies for the Newly Released Implementation Regulations of the 4th Amendment of the Chinese Patent Law: Part 2: Grace Period without Loss of Novelty

7 February 2024

Background As mentioned in our earlier article, the Implementation Regulations of the Chinese Patent Law (“Regulations”, similar to the CFR in the US) were approved in November, and the CNIPA finally made public the full text of the Regulations just before the arrival of the New Year. At the same time, the CNIPA also released […]

CNIPA further clarifies how it counts “delays” when calculating Patent Term Adjustment (PTA) in the new Draft Examination Guidelines and how it affects international applicants

12 April 2023

At the end of October 2022, the China National Intellectual Property Administration (CNIPA) released a new draft amendment of the Patent Examination Guidelines1 (hereinafter referred to as the “New Draft”) to the new Chinese Patent Law that came into effect in 2021. We highlight two key amendments below. 1. The starting date for calculating PTA […]

Our Past Events

Dr. Jacqueline Lui, Ms. Pauli Wong, and Mr. Eddie Ho Named Patent Stars by ManagingIP

Eagle IP Ranked Among Top Tier Firms in IAM Patent 1000

Jennifer Che from Eagle IP to Attend BIO 2025 in Boston!

HKMHDIA Medical Fair Forum

Celebrating Innovation at the Asia Summit for Global Health

Eagle IP Celebrates 20th Anniversary, Reflecting on Two Decades of Excellence

Recommended Insights

FOLLOW UP: Amendments to the China Patent Examination Guidelines in 2022 – Part 1: New rules for designs in view of China signing onto the Hague Agreement

China’s Newest Examination Guidelines: Inventive Step for Biological / Life Science Inventions (Part III)

IP Strategies for the Newly Released Implementation Regulations of the 4th Amendment of the Chinese Patent Law: Part 2: Grace Period without Loss of Novelty

CNIPA further clarifies how it counts “delays” when calculating Patent Term Adjustment (PTA) in the new Draft Examination Guidelines and how it affects international applicants